Cosmo Pharmaceuticals NV
SIX:COPN

Watchlist Manager
Cosmo Pharmaceuticals NV Logo
Cosmo Pharmaceuticals NV
SIX:COPN
Watchlist
Price: 109 CHF 3.42% Market Closed
Market Cap: 1.9B CHF

Relative Value

The Relative Value of one COPN stock under the Base Case scenario is hidden CHF. Compared to the current market price of 109 CHF, Cosmo Pharmaceuticals NV is hidden .

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

COPN Relative Value
HIDDEN
Show
Worst Case
Base Case
Best Case

Valuation Multiples

vs History
46
vs Industry
26
Median 3Y
7
Median 5Y
9.9
Industry
2.6
Forward
12.9
vs History
28
vs Industry
34
Median 3Y
20.5
Median 5Y
20.3
Industry
21.4
Forward
63.7
vs History
55
vs Industry
42
Median 3Y
18.4
Median 5Y
30.3
Industry
16.4
vs History
28
vs Industry
7
Median 3Y
15.5
Median 5Y
5.2
Industry
22.8
vs History
0
vs Industry
40
Median 3Y
2.2
Median 5Y
2.2
Industry
2.2
vs History
46
vs Industry
28
Median 3Y
5.5
Median 5Y
9.2
Industry
2.9
Forward
11.9
vs History
50
vs Industry
36
Median 3Y
8.1
Median 5Y
14
Industry
5.5
vs History
49
vs Industry
38
Median 3Y
13.4
Median 5Y
22.9
Industry
13
Forward
61.9
vs History
41
vs Industry
39
Median 3Y
16.2
Median 5Y
23.2
Industry
16.5
Forward
49.9
vs History
50
vs Industry
45
Median 3Y
13.9
Median 5Y
23.1
Industry
15.6
vs History
53
vs Industry
34
Median 3Y
18.5
Median 5Y
29.6
Industry
18.7
vs History
0
vs Industry
41
Median 3Y
1.9
Median 5Y
2
Industry
1.9

Multiples Across Competitors

COPN Competitors Multiples
Cosmo Pharmaceuticals NV Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
IE
Cosmo Pharmaceuticals NV
SIX:COPN
1.7B CHF 10.3 34 23 27.7
US
Eli Lilly and Co
NYSE:LLY
997.6B USD 16.9 54.7 36.4 39
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP 578.3 -15 783.5 3 846.3 17 702.3
US
Johnson & Johnson
NYSE:JNJ
494.8B USD 5.3 19.6 16.1 20.9
CH
Roche Holding AG
SIX:ROG
263.6B CHF 4.3 28 11.9 13.9
UK
AstraZeneca PLC
LSE:AZN
218.4B GBP 5.1 31.4 108.6 159
CH
Novartis AG
SIX:NOVN
214.5B CHF 4.8 18.7 11.9 15.3
US
Merck & Co Inc
NYSE:MRK
270.7B USD 4.2 14.2 10.1 12
DK
Novo Nordisk A/S
CSE:NOVO B
1.6T DKK 5.2 15.7 11 12.7
IE
Endo International PLC
LSE:0Y5F
213.9B USD 92.2 -73.2 338.7 849.2
US
Pfizer Inc
NYSE:PFE
146.1B USD 2.3 14.9 7.6 10.3
P/E Multiple
Earnings Growth PEG
IE
Cosmo Pharmaceuticals NV
SIX:COPN
Average P/E: 25.7
34
-34%
N/A
US
Eli Lilly and Co
NYSE:LLY
54.7
54%
1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
Negative Multiple: -15 783.5 N/A N/A
US
Johnson & Johnson
NYSE:JNJ
19.6
29%
0.7
CH
Roche Holding AG
SIX:ROG
28
29%
1
UK
AstraZeneca PLC
LSE:AZN
31.4
37%
0.8
CH
Novartis AG
SIX:NOVN
18.7
17%
1.1
US
Merck & Co Inc
NYSE:MRK
14.2
15%
0.9
DK
Novo Nordisk A/S
CSE:NOVO B
15.7
3%
5.2
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -73.2 N/A N/A
US
Pfizer Inc
NYSE:PFE
14.9
27%
0.6
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
IE
Cosmo Pharmaceuticals NV
SIX:COPN
Average EV/EBITDA: 401.9
23
-24%
N/A
US
Eli Lilly and Co
NYSE:LLY
36.4
34%
1.1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
3 846.3
36%
106.8
US
Johnson & Johnson
NYSE:JNJ
16.1
9%
1.8
CH
Roche Holding AG
SIX:ROG
11.9
5%
2.4
UK
AstraZeneca PLC
LSE:AZN
108.6
10%
10.9
CH
Novartis AG
SIX:NOVN
11.9
6%
2
US
Merck & Co Inc
NYSE:MRK
10.1
6%
1.7
DK
Novo Nordisk A/S
CSE:NOVO B
11
1%
11
IE
E
Endo International PLC
LSE:0Y5F
338.7
N/A N/A
US
Pfizer Inc
NYSE:PFE
7.6
0%
N/A
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
IE
Cosmo Pharmaceuticals NV
SIX:COPN
Average EV/EBIT: 1 714.8
27.7
-36%
N/A
US
Eli Lilly and Co
NYSE:LLY
39
36%
1.1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
17 702.3
98%
180.6
US
Johnson & Johnson
NYSE:JNJ
20.9
15%
1.4
CH
Roche Holding AG
SIX:ROG
13.9
6%
2.3
UK
AstraZeneca PLC
LSE:AZN
159
23%
6.9
CH
Novartis AG
SIX:NOVN
15.3
12%
1.3
US
Merck & Co Inc
NYSE:MRK
12
8%
1.5
DK
Novo Nordisk A/S
CSE:NOVO B
12.7
0%
N/A
IE
E
Endo International PLC
LSE:0Y5F
849.2
N/A N/A
US
Pfizer Inc
NYSE:PFE
10.3
7%
1.5